More drugs have high sensitivities for BC patients in cluster 2, including AZD.2281(Olaparib), AZD6244(Selumetinib), Bosutinib, CGP.60474(PKC inhibitor), CI.1040 (MEK inhibitor), Etoposide, GDC.0449(Vismodegib), Gefitinib, Gemcitabine, JNK.9L (JNK inhibitor), Pyrimethamine, Roscovitine, and Temsirolimus. Here, MAP2K7 is linked to breast cancer.